AZD 2281 (Olaparib, KU-0059436) is a novel, potent orally active PARP (poly ADP-ribose polymerase) inhibitorwith IC50 of 5 and 1 nM for PARP-1and PARP-2 respectively. AZD 2281 (Olaparib, KU-0059436) acts as an inhibitor of the enzyme Poly ADP ribose polymerase (PARP) and is one of the first PARP inhibitors.It induces cancer specific synthetic lethality in homologous recombination repair defective cells, including BRCA-deficient tumors. Olaparib is an autophagy and mitophagy activator.
Radiat Oncol. 2022 Aug 19;17(1):144.
Ku70 affects the frequency of chromosome translocation in human lymphocytes after radiation and T-cell acute lymphoblastic leukemia
AZD2281 (Olaparib) purchased from AbMole
Sci Adv. 2022 May 13;8(19):eabn1229.
Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer
AZD2281 (Olaparib) purchased from AbMole
Free Radic Biol Med. 2022 Jan;178:174-188.
DNA damage response proteins synergistically affect the cancer prognosis and resistance
AZD2281 (Olaparib) purchased from AbMole
BMC Biol. 2021 May 20;19(1):108.
Very long intergenic non-coding (vlinc) RNAs directly regulate multiple genes in cis and trans
AZD2281 (Olaparib) purchased from AbMole
Int J Biol Sci. 2021 Jan 31;17(3):689-701.
Preclinical evaluation of radiation therapy of BRCA1-associated mammary tumors using a mouse model
AZD2281 (Olaparib) purchased from AbMole
Cell. 2019 Jun 13;177(7):1903-1914.e14.
Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish.
AZD2281 (Olaparib) purchased from AbMole
Clin Cancer Res. 2019 Mar 1;25(5):1664-1675.
The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity.
AZD2281 (Olaparib) purchased from AbMole
Int J Biol Sci. 2018 Oct 3;14(13):1769-1781.
Inhibition of AKT suppresses the initiation and progression of BRCA1-associated mammary tumors.
AZD2281 (Olaparib) purchased from AbMole
Cell Experiment | |
---|---|
Cell lines | SW620 colorectal cell line |
Preparation method | Potentiation of MMS Cytotoxicity by 47 Determined by the Use of Sulforhodamine B Cell Growth Assays. SW620 cells were seeded in 96-well plates and were left to attach overnight. Cells were preincubated with vehicle control (DMSO) or with a single concentration of KU-0059436 (1, 3, 10, 30, 100 or 300 nM) for 1 h before the addition of increasing concentrations of MMS. Cells were incubated in the presence of each drug combination for 4 days before cell growth was quantified by the use of an SRB assay.44 Data were calculated from triplicate wells as the mean percentage of cell growth relative to KU-0059436-only wells, and (SE and IC50 were calculated by the use of XL-FIT 4 software. SW620 cells showed <24% growth inhibition (>76% cell growth) when only KU-0059436 was used at concentrations below 300 nM (data not shown). |
Concentrations | 1, 3, 10, 100 and 300 nM |
Incubation time | 4 days |
Animal Experiment | |
---|---|
Animal models | mouse bearing SW620 xenografted tumors |
Formulation | methylcellulose/PBS |
Dosages | 10 mg/kg once daily for 5 consecutive days |
Administration | orally |
Molecular Weight | 434.46 |
Formula | C24H23FN4O3 |
CAS Number | 763113-22-0 |
Solubility (25°C) | DMSO 90 mg/mL DMF 45 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[5] Marchetti et al. Expert Opin Investig Drugs. Olaparib , PARP1 inhibitor in ovarian cancer.
Related PARP Products |
---|
PARP/EZH2-IN-1
PARP/EZH2-IN-1 is a first-in-class dual PARP (IC50 6.87 nM) and EZH2 (IC50 36.51 nM) inhibitor for triple-negative breast cancer with wild-type BRCA. |
3',4'-Dimethoxyflavone
3',4'-Dimethoxyflavone is a lipophilic flavone, can be isolated from the leaves of Primula veris. |
VEGFR/PARP-IN-1
VEGFR/PARP-IN-1 is a VEGFR/PARP dual inhibitor (IC50s: 191 nM and 60.9 nM respectively). |
PARP-1-IN-4
PARP-1-IN-4 is a PARP-1 inhibitor. |
PARP-1-IN-13
PARP-1-IN-13 is a PARP-1 inhibitor (IC50: 26 nM). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.